Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma

Fig. 3

Exponential disease-specific OS curves used in model base case. KM, Kaplan–Meier; OS, overall survival; PrePS, pre-progression survival; PPS, post-progression survival; R-CHOP, rituximab with cyclophosphamide, doxorubicin, vincristine and prednisolone; VR-CAP, bortezomib with rituximab, cyclophosphamide, doxorubicin and prednisolone

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us